Stoke Therapeutics Q1 2025 net income $112.9M; advances zorevunersen Phase 3 with Biogen

Stoke Therapeutics, Inc.

2025-Q1 EPS reported $1.90 revenue$158,569,000

Net income $112.9M ($1.90 diluted EPS) in Q1 2025 vs net loss $26.4M ($0.57 per share) in Q1 2024.
Revenue $158.5M, including $152.4M from Biogen license fee and $6.1M from Acadia partnership.
Cash position $380.3M as of Mar 31, 2025; projected to fund operations beyond mid-2028.
Phase 3 EMPEROR study of zorevunersen for Dravet syndrome cleared with FDA, EMA, PMDA; enrollment in Q2 2025.
Biogen collaboration: $165M upfront, potential $385M milestones, tiered royalties; Stoke retains North America rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.